Kopsavilkums
Several novel cyclic MSH analogs were synthesized, and their binding properties were tested on cells transiently expressing the human melanocortin-1 (MC1), MC3, MC4, and MC5 receptors. We discovered a novel substance (HS024) that showed about 20-fold selectivity and very high affinity (K(i) = 0.29 nM) for the MC4 receptor. HS024 (cyclic [AcCys3,Nle4,Arg5,D-Nal7,Cys-NH211]α-MSH-(3-11)) has a 29-membered atom ring structure that includes an Arg in position 5. HS024 was found to antagonize an αMSH-induced cAMP response in cells expressing the human MC1, MC3, MC4, and MC5 receptor DNAs. HS024 also caused a dose-dependent increase in food intake, with a maximum response (4-fold increase) at a 1-nmol dose injected intracerebroventricularly in free feeding rats. We also tested SHU9119, a previously described nonselective MC receptor antagonist, and found HS024 and SHU9119 to have similar potencies for increasing food intake, although SHU9119 appeared to induce more serious side-effects. HS024 increased the food intake of free feeding rats to levels comparable to those in food-deprived rats, indicating that blockade of the MC4 receptor is a highly effective way to increase feeding. Moreover, we tested the effects of intracerebroventricular rejections of HS024 in elevated plus-maze and open- field experiments on rats. In these tests, HS024 did not appear to affect emotionality or locomotor activity, suggesting that the MC4 receptor does not mediate the anxiogenic-like and locomotor effects related to the melanocortic peptides.
| Oriģinālvaloda | Angļu |
|---|---|
| Lapas (no-līdz) | 5006-5014 |
| Lapu skaits | 9 |
| Žurnāls | Endocrinology (United States) |
| Sējums | 139 |
| Izdevuma numurs | 12 |
| DOIs | |
| Publikācijas statuss | Publicēts - 1998 |
| Ārēji publicēts | Jā |
ANO IAM
Šis izpildes rezultāts palīdz sasniegt šādus ANO ilgtspējīgas attīstības mērķus (IAM)
-
3. IAM — Laba Veselība un Labbūtība
Nospiedums
Uzziniet vairāk par pētniecības tēmām “Discovery of a novel superpotent and selective melanocortin-4 receptor antagonist (HS024): Evaluation in vitro and in vivo”. Kopā tie veido unikālu nospiedumu.Citēt šo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver